Navigation Links
First-in-class treatment for acute leukemia
Date:12/8/2009

think it has the potential to make a big difference in the treatment of AML. In fact the European Medicines Agency has designated AML an orphan disease as there is a big medical need and no other treatment available." For AML treatment, the new drug is anticipated to achieve the same result as marrow bone transplantations 50-70% of patients surviving and improving.

Although there are already other therapies for chronic myeloid leukaemia, there is still a need for better treatment options. When one of the main existing treatments for CML was introduced, it quickly reached a market of over $1 billion a year. There are about the same number of patients with AML and CML in the western world, so the market for a new effective cancer treatment is very promising.

Fruitful partnership

This particularly successful EUREKA project built on the complementary skills of the small innovative and dynamic biotech company and the larger pharmaceutical company, with its technology base and experience of clinical drug development. The project was financially supportive to Innate Pharma; particularly important in the early stages by enabling investigative work that would otherwise not have been possible from the start. This generated a momentum and early progress that helped win further investment from Novo Nordisk during the collaboration, Novo Nordisk became a main investor in Innate Pharma.

The Danish company benefited through sharing Innate Pharma's early concept, and by gaining access to Innate Pharma's patents on the strategic approach to the drug design. This was critical to the project and laid the foundation for a larger series of patent applications filed by the two companies in collaboration. The French company's patent platform and technical competences were complemented by drug-discovery and clinical skills from the Danish partner.


'/>"/>

Contact: Francois Romagn
Francois.Romagne@innate-pharma.fr
33-430-303-030
EUREKA
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Presence of gene mutation helps guide thyroid cancer treatment
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. New genetic research into nicotine addiction shows promise for personalized treatment
7. Interleukin-8, key marker for colorectal cancer treatment
8. New class of drug offers hope to treatment-resistant AIDS patients
9. Paradigm shift in Alzheimerss research: new treatments
10. New research on structure of bones raises questions for treatment of osteoporosis
11. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... cooks are turning to more healthful alternatives to their ... sometimes mean low satisfaction. Now researchers are reporting new ... that are made with olive oil rather than pork ... of Agricultural and Food Chemistry . , Ana M. ... to expect just the right amount of chewiness and ...
(Date:7/9/2014)... fossil from China challenges the commonly held belief that ... ability to fly. The birdlike fossil is actually not ... remains of a tiny tree-climbing animal that could glide, ... in Blanding, Utah, and Alan Feduccia of the University ... Journal of Ornithology . , The fossil of the ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... announced a partnership with Toyota to support efforts ... of the Philippines Peablanca Protected Landscape and Seascape ... of the nations main islands. In addition ... additional benefits from agroforestry projects under the three-year ...
... Questions remain unresolved as to whether the Neanderthals ... or because of deteriorating climatic conditions. Although scientists ... has been difficult to pinpoint the climatic character ... new study by an international team of researchers, ...
... This release is available in German . , ... the climate and ecosystem of the Arctic Ocean,Bremerhaven, September 13, ... one metre thick this year, equating to an approximate 50 ... the initial results from the latest Alfred-Wegener-Institute for Polar and ...
Cached Biology News:Conservation International and Toyota partner to protect Philippines' rain forests 2Conservation International and Toyota partner to protect Philippines' rain forests 3Climate -- no smoking gun for Neanderthals 2The sea ice is getting thinner 2The sea ice is getting thinner 3The sea ice is getting thinner 4
(Date:1/15/2014)...   Niagara Thermal Products is proud to announce ... LLC ("B3") as the critical thermal component supplier in ... Army Corps of Engineers.  B3 has developed the only ... and destroys VOCs and other chemical pollutants, allergens and ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... , January 15, 2014 A study ... races on the Formula 1 track could help to tackle ... Applied Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) ... healthcare provider Simplyhealth. Telemetry technology, which is inspired ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , , , , ... at 1 p.m. EDT, Sunday, Aug. 23, to discuss new science experiments ... from NASA,s Kennedy Space Center in Florida and will be broadcast live ... ) , , Media are invited to ...
... Md., Aug. 20 Martek Biosciences Corporation (Nasdaq: MATK ... supply agreement with Milk Powder Solutions, based in Australia. Under the ... exclusive supplier for all of its ARA needs for infant formula ... , , "This new agreement with Milk Powder ...
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ; ... Option(TM) Inferior Vena Cava (IVC) Filter in the United ... limited pre-launch in July. Angiotech holds exclusive worldwide rights ... it obtained in a license agreement with privately held ...
Cached Biology Technology:NASA Sets Briefing on New Space Station Science Experiments 2Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions 2Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions 3Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States 2Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States 3Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States 4Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States 5
... COOLSCOPE is an integrated digital microscope and ... computer, equipment setup, optical adjustment or software ... innovative technology, COOLSCOPE combines simplicity and advanced ... COOLSCOPE offers simultaneous viewing of a macro ...
... kit provides complete components including positive ... detection of DNA fragmentation in cultured ... of BrdU in the procedure provides ... methods. Results can be analyzed by ...
... Life Science LAS-3000 imaging system combines ... simplified user interface, providing significantly improved ... of modularities. The system is especially ... perfect standard system for Western blotting ...
... Science LAS-3000mini is a compact image ... applications, and the perfect standard system ... LAS-3000 provides significantly improved system sensitivity ... calibration standards validate that Fujis LAS-3000 ...
Biology Products: